Moose, If Auph dosing protocol patent applies only for Lupus Nephritis, then they may have a sliver of a case for the other indication(Eye treatment ) as the litigation involves only patent infringement for the eye condition. I think Voclosporin trial data for this indication is not strong enough that’s why they shelved it. I don’t know if Auph applied for a patent on the dosing protocol like the one they did for LN.
News 
Market Data 
Discover 
AI
